Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.81 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.82 +9.7% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.81 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.82 +9.7% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
Earnings Routine +

PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results

PharmaCorp Rx Confirms M&A Execution but Stock Stalls Near Dilutive Offering Price

By The Northwire Desk — AI Analysis Apr 29, 2026 · 20:51 PCRX · 0.43 PharmaCorp Rx Inc.
Executive Summary
  • Event: PharmaCorp announced Fourth Quarter and Fiscal Year 2025 Financial Results on April 29, 2026.
  • Revenue Growth: FY2025 revenue reached $20.9 million, a significant increase from $5.8 million in the previous fiscal year (260% YoY growth). Q4 2025 revenue was $7.7 million, up 75% from Q4 2024 ($4.4 million).
  • Profitability: Adjusted EBITDA improved to $3.5 million in FY2025 compared to $0.85 million in 2024. However, Net Loss widened slightly for the full year to $1.4 million (from $1.1 million in 2024), though Q4 net loss narrowed to $0.64 million from $0.72 million.
  • Cash Position: Cash reserves strengthened to $25.9 million at year-end, up from $12.9 million at the end of 2024.
  • Operations: Same-store sales increased 6% in Q4; prescription script count increased 3.8%. Three pharmacies were acquired and integrated (two Western Canada, one Eastern Canada) for $8.7 million total consideration.
  • Financing Context: The cash increase is largely attributed to a bought deal public offering closed on November 12, 2025, raising approximately $23 million gross proceeds at C$0.42 per unit.
Material Impact
  • Execution Confirmation: This news primarily confirms the execution of strategies announced in late 2025 (acquisitions and financing). The revenue growth aligns with the acquisition of three pharmacies closed in October 2025, which was already public knowledge.
  • Financial Health: The doubling of cash reserves ($12.9M to $25.9M) reduces immediate liquidity risk but comes at the cost of significant dilution (54.8 million units issued).
  • Profitability Concerns: While EBITDA improved, the widening full-year net loss ($1.4M vs $1.1M) despite tripling revenue suggests high integration costs or one-time expenses that are not yet fully absorbed. This is a critical risk factor for long-term valuation.
  • Market Reaction: The stock price ($0.43) remains barely above the dilutive offering price ($0.42), indicating the market has already priced in this growth and remains cautious about future profitability and warrant overhang.
  • Conclusion: The news is positive regarding top-line growth and cash liquidity but routine as it validates previously announced M&A activity without introducing new, unexpected catalysts.
PCRX · Price
Company Overview
  • Overview: PharmaCorp Rx Inc. operates as a pharmacy operator in Canada, focusing on acquiring independent pharmacies and integrating them under the PharmaChoice Canada banner.
  • Flagship Project: The national consolidation strategy involves acquiring community pharmacies to expand footprint and leverage operational efficiencies across a unified network.
  • Development: As of April 2026, the company operates seven PharmaChoice Canada bannered pharmacies following recent acquisitions in Western and Eastern Canada.
Read the original news release →

More from PharmaCorp Rx Inc.

Jun 29, 2026 · 07:16

PharmaCorp Announces Definitive Agreement to Acquire Western Canada PharmaChoice Bannered Pharmacy

M&A / Property Jun 01, 2026 · 09:00

PharmaCorp Rx Inc. Consolidates Eastern Canada Footprint as Q1 Revenue Surges 79%, Yet Margin Compression and Integration Pace Demand Caution

Earnings May 25, 2026 · 09:27

PharmaCorp Rx Advances National Footprint with Definitive Acquisition, Pipeline Execution Validates Growth Strategy

M&A / Property May 01, 2026 · 17:00

PharmaCorp Rx Inc.

M&A / Property Apr 30, 2026 · 11:04

PharmaCorp Doubles Footprint, Cash Reserves Depleted by Aggressive Buyout

M&A / Property Dec 11, 2025 · 19:04

Pharmacorp Rx enters deal to acquire pharmacy files

M&A / Property